Omalizumab (Xolair®) ELISA Kit
Enzyme immunoassay for the quantitative determination of Omalizumab (Xolair®) in serum and plasma.Enzyme immunoassay for the quantitative determination of omalizumab (Xolair®) in serum and plasma. ELISA Genie® omalizumab ELISA has been especially developed for the quantitative analysis omalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations indicated in the pharmacokinetics section of prospectus..
|Required Volume (μl)||10|
|Total Time (min)||70|
|Sample Type||Serum, Plasma|
|Number of Assays||96|
|Detection Limit (ng/mL)||10 (ng/mL)|
|Spike Recovery (%)||85-115%|
|Shelf Life (year)||1|
About Omalizumab (Xolair®)
A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. Most likely removed by opsonization via the reticuloendothelial system. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.
Omalizumab (Xolair®) ELISA Kit test principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtitre plate coated with the reactant specific for omalizumab (Xolair®). Following incubation wells are washed and then horse radish peroxidase (HRP) conjugate is added and binds to omalizumab. After incubation, the wells are washed, and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of omalizumab (Xolair®) in the sample or standard. Results of samples can be determined directly using the standard curve.
Xolair® is a trademark of Novartis AG.